Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the...

Full description

Bibliographic Details

Published in:	The Lancet. Haematology Vol. 9; no. 9; p. e648
Main Authors:	de Latour, Régis Peffault, Szer, Jeff, Weitz, Ilene C, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos M, Nishimori, Hisakazu, Ajayi, Temitayo, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio M, Hillmen, Peter
Format:	Journal Article
Language:	English
Published:	01.09.2022
ISSN:	2352-3026, 2352-3026
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!